List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8852300/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts. Journal of Allergy and Clinical Immunology, 2022, 149, 1373-1382.e12.	1.5	30
2	Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune) Tj ETC 359-371.	)q0 0 0 rgB 6.3	T /Overlock 1 139
3	Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy. Journal of Allergy and Clinical Immunology, 2022, 149, 2166-2170.e1.	1.5	30
4	Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research. Journal of Allergy and Clinical Immunology, 2021, 147, 992-1003.e5.	1.5	34
5	A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol. Journal of Allergy and Clinical Immunology, 2020, 145, 1292-1295.e1.	1.5	12
6	Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy. Journal of Allergy and Clinical Immunology, 2020, 146, 851-862.e10.	1.5	53
7	Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. Journal of Allergy and Clinical Immunology, 2020, 146, 863-874.	1.5	63
8	Impact of food allergy on food insecurity and health literacy in a tertiary care pediatric allergy population. Pediatric Allergy and Immunology, 2019, 30, 363-369.	1.1	26
9	Clinical factors associated with peanut allergy in a highâ€risk infant cohort. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2199-2211.	2.7	18
10	Development and Application of a Functional Human Esophageal Mucosa Explant Platform to Eosinophilic Esophagitis. Scientific Reports, 2019, 9, 6206.	1.6	5
11	Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy. JAMA - Journal of the American Medical Association, 2019, 321, 946.	3.8	206
12	The Consortium for Food Allergy Research (CoFAR): The first generation. Journal of Allergy and Clinical Immunology, 2019, 143, 486-493.	1.5	18
13	Acetaminophen is both bronchodilatory and bronchoprotective in human precision cut lung slice airways. Xenobiotica, 2019, 49, 1106-1115.	0.5	3
14	Effects of rhinovirus 39 infection on airway hyperresponsiveness to carbachol in human airways precision cut lung slices. Journal of Allergy and Clinical Immunology, 2018, 141, 1887-1890.e1.	1.5	22
15	Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector TH2 subsets. Journal of Allergy and Clinical Immunology, 2018, 141, 2107-2120.	1.5	88
16	Delivery of high-quality pediatric spirometry in rural communities: A novel use for telemedicine. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1042-1044.	2.0	12
17	Advances in the approach to the patient with food allergy. Journal of Allergy and Clinical Immunology, 2018, 141, 2002-2014.	1.5	13
18	Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 476-485.e3.	2.0	153

#	Article	IF	CITATIONS
19	AR101 Oral Immunotherapy for Peanut Allergy. New England Journal of Medicine, 2018, 379, 1991-2001.	13.9	518
20	Successful desensitization in a pediatric patient with acetazolamide allergy. Annals of Allergy, Asthma and Immunology, 2018, 121, 508-509.	0.5	1
21	Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel. Journal of Allergy and Clinical Immunology, 2017, 139, 29-44.	1.5	374
22	Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–Sponsored Expert Panel. Journal of Pediatric Nursing, 2017, 32, 91-98.	0.7	14
23	Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–Sponsored Expert Panel. Pediatric Dermatology, 2017, 34, e1-e21.	0.5	20
24	Addendum guidelines for the prevention of peanut allergy in the United States. Pediatric Dermatology, 2017, 34, 5-12.	0.5	17
25	Impact of granulocyte contamination on PBMC integrity of shipped blood samples: Implications for multi-center studies monitoring regulatory T cells. Journal of Immunological Methods, 2017, 449, 23-27.	0.6	8
26	Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel. Annals of Allergy, Asthma and Immunology, 2017, 118, 166-173.e7.	0.5	59
27	Food Allergy. New England Journal of Medicine, 2017, 377, 1168-1176.	13.9	69
28	Food Allergy. New England Journal of Medicine, 2017, 377, 2294-2295.	13.9	7
29	Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. Journal of Allergy and Clinical Immunology, 2017, 139, 1242-1252.e9.	1.5	265
30	Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. Journal of Allergy and Clinical Immunology, 2017, 139, 882-888.e5.	1.5	100
31	Transcriptional Profiling of Egg Allergy and Relationship to Disease Phenotype. PLoS ONE, 2016, 11, e0163831.	1.1	30
32	Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology, 2016, 137, 1117-1127.e10.	1.5	149
33	Early-life gut microbiome composition and milk allergy resolution. Journal of Allergy and Clinical Immunology, 2016, 138, 1122-1130.	1.5	307
34	Safety of epicutaneous immunotherapy for the treatment of peanut allergy: AÂphase 1 study using the Viaskin patch. Journal of Allergy and Clinical Immunology, 2016, 137, 1258-1261.e10.	1.5	91
35	Current and Emerging Therapies for IgE-Mediated Food Allergy. Current Allergy and Asthma Reports, 2016, 16, 28.	2.4	11
36	Impact of Allergic Reactions on Food-Specific IgE Concentrations and Skin Test Results. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 239-245.e4.	2.0	20

#	Article	IF	CITATIONS
37	Egg-Specific IgA and IgA2 Are Associated with Sustained Unresponsiveness to Egg Following Oral Immunotherapy. Journal of Allergy and Clinical Immunology, 2015, 135, AB38.	1.5	1
38	Diagnosis, Management, and Investigational Therapies for Food Allergies. Gastroenterology, 2015, 148, 1132-1142.	0.6	31
39	Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. Journal of Allergy and Clinical Immunology, 2015, 135, 1240-1248.e3.	1.5	160
40	Correlations between basophil activation, allergen-specific IgE with outcome and severity of oral food challenges. Annals of Allergy, Asthma and Immunology, 2015, 114, 319-326.	0.5	74
41	State of the art on food allergen immunotherapy: Oral,Âsublingual, and epicutaneous. Journal of Allergy and Clinical Immunology, 2014, 133, 318-323.	1.5	172
42	Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 133, 468-475.e6.	1.5	375
43	Immunomodulatory Effect of Active Treatment Options in Food Allergy. Current Treatment Options in Allergy, 2014, 1, 133-144.	0.9	1
44	The natural history of egg allergy in an observational cohort. Journal of Allergy and Clinical Immunology, 2014, 133, 492-499.e8.	1.5	229
45	Pneumococcal meningitis in a patient with IL-1 receptor–associated kinase-4 deficiency: A case of failed prophylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 700-703.	2.0	1
46	Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison. Journal of Allergy and Clinical Immunology, 2013, 132, 476-478.e2.	1.5	86
47	Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. Journal of Allergy and Clinical Immunology, 2013, 131, 128-134.e3.	1.5	171
48	Sublingual immunotherapy for peanut allergy: AÂrandomized, double-blind, placebo-controlled multicenter trial. Journal of Allergy and Clinical Immunology, 2013, 131, 119-127.e7.	1.5	268
49	Allergic Reactions to Foods in Preschool-Aged Children in a Prospective Observational Food Allergy Study. Pediatrics, 2012, 130, e25-e32.	1.0	223
50	Oral Immunotherapy for Treatment of Egg Allergy in Children. New England Journal of Medicine, 2012, 367, 233-243.	13.9	606
51	Effects of the Î <sup>2</sup> -agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of β2-adrenergic receptors with N-terminal polymorphisms. Cell Biology International, 2012, 36, 1171-1183.	1.4	9
52	A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response. Journal of Allergy and Clinical Immunology, 2011, 127, 654-660.	1.5	488
53	Mechanisms of immune tolerance relevant to food allergy. Journal of Allergy and Clinical Immunology, 2011, 127, 576-584.	1.5	151
54	A phase II, randomized, doubleâ€ʻblind, parallelâ€ʻgroup, placeboâ€ʻcontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. Journal of Allergy and Clinical Immunology, 2011, 127, 1309-1310.e1.	1.5	234

3

#	Article	IF	CITATIONS
55	Peanut oral immunotherapy is not ready for clinical use. Journal of Allergy and Clinical Immunology, 2010, 126, 31-32.	1.5	100
56	Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panel. Journal of Allergy and Clinical Immunology, 2010, 126, S1-S58.	1.5	1,149
57	Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. Journal of Allergy and Clinical Immunology, 2010, 126, 1105-1118.	1.5	1,614
58	Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Annals of Allergy, Asthma and Immunology, 2010, 105, 444-450.	0.5	137
59	Oral immunotherapy for food allergy. Current Allergy and Asthma Reports, 2009, 9, 186-193.	2.4	44
60	Safety of a peanut oral immunotherapy protocol in children with peanut allergy. Journal of Allergy and Clinical Immunology, 2009, 124, 286-291.e6.	1.5	252
61	Clinical efficacy and immune regulation with peanut oral immunotherapy. Journal of Allergy and Clinical Immunology, 2009, 124, 292-300.e97.	1.5	610
62	Adverse reactions during peanut oral immunotherapy home dosing. Journal of Allergy and Clinical Immunology, 2009, 124, 1351-1352.	1.5	179
63	Characterization of a panel of six $\hat{l}^22$ -adrenergic receptor antibodies by indirect immunofluorescence microscopy. Respiratory Research, 2008, 9, 32.	1.4	5
64	Egg oral immunotherapy in nonanaphylactic children with egg allergy. Journal of Allergy and Clinical Immunology, 2007, 119, 199-205.	1.5	357
65	The β-agonist isoproterenol attenuates EGF-stimulated wound closure in human airway epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L485-L491.	1.3	11
66	Occupational asthma symptoms and respiratory function among aerial pesticide applicators. American Journal of Industrial Medicine, 2003, 43, 407-417.	1.0	16
67	Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer. BMC Pharmacology, 2003, 3, 15.	0.4	10
68	EGF receptor downregulation depends on a trafficking motif in the distal tyrosine kinase domain. American Journal of Physiology - Cell Physiology, 2002, 282, C420-C433.	2.1	32
69	Molecular Cloning and Functional Characterization of a Vasotocin Receptor Subtype That Is Expressed in the Shell Gland and Brain of the Domestic Chicken1. Biology of Reproduction, 2000, 62, 8-15.	1.2	56
70	The role of food allergy and other allergic disease in atopic dermatitis. Clinical Reviews in Allergy and Immunology, 1999, 17, 293-321.	2.9	4
71	Diagnosis of post-bone marrow transplant pulmonary lymphoproliferative disorder by bronchoalveolar lavage. , 1998, 25, 67-70.		4

72 Clinical Manifestations of Food Allergic Disease. , 0, , 1-17.